Feasibility study of agjuvant chemotherapy with docetaxel, cisplatin and fluorouracil for esophageal cancer
- Conditions
- esophageal cancer
- Registration Number
- JPRN-UMIN000009150
- Lead Sponsor
- Shimane University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Not provided
1) Past history of drug allergy 2)Past history of drug allergy of docetaxel, cisplati and fluorouracil 3)Patient with clinically obvious infecton 4)Women who are pregnant, breastfeeding, or potentially (hoping to become) pregnant 5)Disease that is serious or requires hospitalization, or history of such disease within past year 6)Difficulty to join the trial due to psychosis or psychotic symptoms or central nervous system damage 7)Massive pleural effusion, ascites and pericardial effusion 8)Gastrointestinal hemorrhage 9)Chronic diarrhea (watery stool or 4 times or more/day) 10)Active hepatitis type HBs positive 11)More than one cancer at the same time or more than one cancer at different times separated by a 5-year disease-free interval. However, multiple active cancers do not include carcinoma in situ or skin cancer which is determined to have been cured as a result of treatment. 12)Otherwise determined by investigators or site principal investigators to be unsuitable for participation in study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Completion rate of 2 cycles
- Secondary Outcome Measures
Name Time Method Adverse event Adverse eventProgression free survival Overall survival